VANCOUVER, British Columbia, July 20, 2017 -- Identillect Technologies Corp. (the “Company” or “Identillect”) (TSX-V:ID) (OTCQB:IDTLF) (Frankfurt:8ID) a trusted leading provider of SaaS email security, is pleased to announce that it has received over $1.3 million in financing proceeds from the early exercise of share purchase warrants. A total of 13,126,268 common shares have been issued through the exercise of an equivalent number of warrants at ten cents per share, representing in excess of 80% of all issued and outstanding warrants.
Identillect CEO Todd Sexton stated, “The early exercise of these warrants strengthens our balance sheet and provides us with additional capital that we will utilize to accelerate our growth by expanding marketing and sales programs which have already been implemented.”
No commissions or placement fees have been paid in relation to the funds received from this warrant exercise. Identillect extends its thanks to its loyal shareholders for their continued support through this early exercise of warrants.
About Identillect
Identillect Technologies is the leading provider of email encryption service Delivery Trust™, empowering enterprises of all sizes to protect their business and their client’s critical information against cyber security attacks.
Delivery Trust™ is an award winning, multi-platform plug-in, which gives users complete control of their emails, for one low price, one simple integration, complies with all regulations and most importantly provides peace of mind.
For more information, or your free trial, please visit www.identillect.com
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
This news release may include forward-looking statements that are subject to risks and uncertainties. All statements within, other than statements of historical fact, are to be considered forward looking. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include market prices, exploitation and exploration successes, continued availability of capital and financing, and general economic, market or business conditions. There can be no assurances that such statements will prove accurate and, therefore, readers are advised to rely on their own evaluation of such uncertainties. We do not assume any obligation to update any forward-looking statements except as required under the applicable laws.
On Behalf of the Board of Directors of: IDENTILLECT TECHNOLOGIES CORP. Todd Sexton Chief Executive Officer Tel: (949) 468-7878 Email: [email protected] Investor Relations: Arlen Hansen Kin Communications 1-866-684-6730 [email protected]


Hanwha Signals Readiness to Build Nuclear-Powered Submarines at Philly Shipyard for U.S. Navy
Hyundai Recalls Over 51,000 Vehicles in the U.S. Due to Fire Risk From Trailer Wiring Issue
Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market
Texas App Store Age Verification Law Blocked by Federal Judge in First Amendment Ruling
Niigata Set to Approve Restart of Japan’s Largest Nuclear Power Plant in Major Energy Shift
DOJ Reaches Settlement With Blackstone’s LivCor Over Alleged Rent Price-Fixing
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement
GLP-1 Weight Loss Pills Set to Reshape Food and Fast-Food Industry in 2025
BP Nears $10 Billion Castrol Stake Sale to Stonepeak
Nike Stock Jumps After Apple CEO Tim Cook Buys $2.9M Worth of Shares
BlackRock-Backed Global Ports Deal Faces Uncertainty Amid Cosco Demands
Waymo Plans Safety and Emergency Response Upgrades After San Francisco Robotaxi Disruptions
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study 



